Fig. 2From: A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathyPatient response to Eculizumab therapy. 93% of patients to whom eculizumab was administered responded favourably. Of these 46% were withdrawn from treatment, 18% remained on treatment at follow up and 36% had no data availableBack to article page